

Influvac[®] 2006 (southern hemisphere)
Composition according to recommendations by WHO and TGA (Australia)

The composition of Influvac[®] 2006, Solvay Pharmaceuticals' influenza vaccine for the influenza season 2006 in the southern hemisphere is as follows:

A/California/7/2004 (H3N2) – like strain (A/New York/55/2004 (NYMC X-157) reass.)	(15 µg haemagglutinin/dose)
A/New Caledonia/20/99 (H ₁ N ₁) – like strain (A/New Caledonia/20/99 IVR-116 reass.)	(15 µg haemagglutinin/dose)
B/Malaysia/2506/2004 – like strain (B/Malaysia/2506/2004)	(15 µg haemagglutinin/dose)

The recommendation of the World Health Organization for the composition of influenza virus vaccines for use in the 2006 season in the southern hemisphere as published in the Weekly Epidemiological Record, No. 40, 2005, **80**, 342-347 (7 October 2005):

- an A/California/7/2004 (H3N2) – like virus [⊖]
- an A/New Caledonia/20/99 (H₁N₁)-like virus
- a B/Malaysia/2506/2004-like strain

[⊖] currently used vaccine virus is A/New York/55/2004 (NYMC X-157) reass.

The recommendations of the Australian Influenza Vaccine Committee (AIVC) on Influenza Vaccines (published by the Therapeutic Goods Administration on 6 October 2005 – File No.: (2004/069330) 2005/6 October 2005) and the Department of Health of the Republic of South Africa for the strains suitable for the vaccine are as follows:

- H₁N₁ strain
A/New Caledonia/20/99 (IVR-116) is a suitable A/New Caledonia/20/99 (H₁N₁)-like strain.
- H₃N₂ strain
A/New York/55/2004 (NYMC X-157) is a suitable A/California/7/2004 (H₃N₂)-like strain.
- B strain
B/Malaysia/2506/2004 is a suitable B/Malaysia/2506/2004-like strain.

Regulatory Affairs Europe
Weesp, 11 October 2005